Understanding Polypharmacy in the Context of Diabetes and Aging

Polypharmacy, commonly defined as the concurrent use of five or more medications, is a pervasive issue among older adults living with diabetes. As the global population ages, the intersection of diabetes management and age-related multimorbidity becomes increasingly complex. Primary care clinicians frequently encounter patients prescribed insulin, oral hypoglycemics, antihypertensives, statins, anticoagulants, and medications for pain, depression, or osteoporosis, often resulting in regimens that exceed ten drugs. This article provides an authoritative, evidence-based framework for identifying, assessing, and mitigating polypharmacy-related risks in older adults with diabetes in primary care.

Prevalence and Contributing Factors

Approximately 40% of older adults with diabetes are affected by polypharmacy, with rates climbing in institutionalized or frail populations. The primary driver is the clustering of comorbidities: hypertension affects up to 75% of older diabetic patients, hyperlipidemia about 65%, and cardiovascular or renal disease a substantial proportion. Each new condition invites additional guideline-recommended medications, creating a cascade effect. Age-related physiological changes—reduced renal function, altered drug metabolism, increased sensitivity to central nervous system agents—further elevate the risk of adverse drug reactions. Additionally, patients may accumulate medications from multiple specialists without adequate reconciliation, amplifying the potential for harmful interactions or duplicate therapy.

Clinical Consequences

Polypharmacy in older adults with diabetes significantly raises the likelihood of adverse drug events, falls, cognitive impairment, and hypoglycemia. Drug interactions involving oral hypoglycemics and beta-blockers, or ACE inhibitors and potassium-sparing diuretics, are particularly perilous. Beyond safety, medication burden erodes adherence: patients with complex, high-pill-count regimens are up to 60% more likely to skip doses or abandon therapy entirely. This non-adherence paradoxically worsens glycemic control and increases emergency visits. Polypharmacy also contributes to prescribing cascades, where one medication’s side effect is mistakenly treated with another drug, perpetuating the cycle. Recognition of these consequences has spurred the development of systematic approaches to deprescribing and regimen optimization.

Key Strategies for Mitigating Polypharmacy Risks

Medication Reconciliation

Medication reconciliation is the foundational step in any polypharmacy management strategy. Clinicians should perform a structured, comprehensive review of all prescribed, over-the-counter, and herbal products at every patient encounter—or at least annually for stable patients. Using the Beers Criteria and the STOPP/START criteria helps identify potentially inappropriate medications for older adults. For example, long-acting sulfonylureas such as glyburide are recommended to be avoided in older adults with diabetes due to prolonged hypoglycemia risk. Reconciliation should also verify dosing appropriateness relative to renal function (e.g., metformin contraindicated if eGFR below 30 mL/min/1.73 m²). Integrating reconciliation with electronic health record decision support can flag drug-drug interactions or therapeutic duplication, such as simultaneous use of DPP-4 inhibitors and GLP-1 receptor agonists without clear rationale.

Deprescribing as a Deliberate Process

Deprescribing—the planned, supervised reduction or discontinuation of medications that are no longer indicated, ineffective, or where the risks outweigh the benefits—is central to managing polypharmacy. Evidence-based deprescribing guidelines exist for antihyperglycemics, antihypertensives, statins, and benzodiazepines. For older adults with diabetes, deprescribing decisions must balance strict glycemic targets against the risk of hypoglycemia. In patients with limited life expectancy or advanced frailty, a less stringent A1c goal (8.0–8.5%) may obviate the need for multiple agents. A practical approach is to begin with medications that have the highest harm potential or the smallest net benefit. For instance, discontinuing a sulfonylurea while maintaining a sodium-glucose cotransporter-2 (SGLT2) inhibitor that offers cardiovascular and renal protection, or reducing an ACE inhibitor dose if asymptomatic hypotension occurs. Always taper when stopping medications that require gradual weaning (e.g., beta-blockers, antidepressants) to prevent rebound events.

Simplifying Regimens

Reducing pill burden through regimen simplification directly improves adherence and reduces cognitive load. Strategies include switching to fixed-dose combination pills (e.g., metformin plus an SGLT2 inhibitor or DPP-4 inhibitor), choosing once-daily agents over twice- or thrice-daily formulations, aligning multiple medications to a single administration time, and eliminating unnecessary supplements (e.g., fish oil, vitamin B12 without deficiency). For insulin-requiring patients, transitioning from a basal-bolus regimen to a simpler twice-daily premixed insulin may be appropriate when hypoglycemia awareness is poor or injection assistance is limited. The goal is not to achieve perfect glycemic control but to optimize quality of life while maintaining safety. Clinicians should also evaluate whether every preventive medication (statins, aspirin, bisphosphonates) remains aligned with the patient’s current goals and life expectancy.

Enhancing Patient Engagement and Shared Decision-Making

Patients and caregivers often lack awareness of why each pill is prescribed, creating a passive “pill pile” rather than an intentional therapeutic strategy. Engaging patients in active medication decision-making improves adherence and reduces the likelihood of discontinuation due to side effects. Primary care providers should use plain language to explain each drug’s purpose, expected benefit, and potential risks, then ask open-ended questions such as, “If you could stop one medication, which would you choose and why?” Tools like the Medication Appropriateness Index can be adapted for collaborative use. For diabetic patients with cognitive impairment, involve a family caregiver in the review process. Emphasize that deprescribing is a trial, not a failure—patients can restart a medication if condition worsens. Shared decision-making respects the patient’s values and avoids the perception that the doctor is simply “cutting corners.”

Interdisciplinary Collaboration

No single provider can effectively manage polypharmacy in complex older adults. An interdisciplinary team—including clinical pharmacists, diabetes educators, nurses, social workers, and geriatricians—spreads cognitive load and brings diverse expertise. Clinical pharmacists can perform comprehensive medication reviews, identify interactions, and suggest substitutions or discontinuations backed by pharmacokinetic data. Diabetes educators can assess injection technique, glucose monitoring burden, and dietary factors that influence medication need. Social workers help address financial barriers to obtaining all medications, which can lead to partial fills and chaotic regimens. Regular team huddles, shared electronic notes, and patient-centered decision-making meetings ensure that each provider’s recommendations coalesce into a coherent, simplified plan. When a specialized geriatric clinic or pharmacy service is available, a referral for a formal comprehensive medication management visit is strongly advised.

The Primary Care Provider’s Role in Polypharmacy Management

Primary care providers are uniquely positioned to orchestrate polypharmacy management due to continuity of care and comprehensive scope. They should adopt a proactive, longitudinal approach rather than reacting only when an adverse event occurs. This involves embedding medication reviews into routine diabetes follow-ups (every 3–6 months for older adults), maintaining a current medication list in the chart, and periodically re-evaluating whether each drug still serves its original purpose. When a patient is admitted to or discharged from a hospital, a reconciliation within 72 hours is critical—discharge medication lists often diverge significantly from pre-admission regimens, with errors causing rehospitalizations. Providers should also be attuned to prescribing cascades: for example, if a patient starts a calcium channel blocker and later develops peripheral edema, consider reducing the dose or switching to an alternative before adding a diuretic.

Tools and Resources

Several validated tools assist in deprescribing decisions. The American Geriatrics Society Beers Criteria lists drugs to avoid or use with caution in older adults, updated every three years. The STOPP/START criteria (Screening Tool of Older People’s Prescriptions/Screening Tool to Alert to Right Treatment) provide explicit rules for appropriate prescribing. For diabetes-specific polypharmacy, the American Diabetes Association Standards of Care in Diabetes—especially the section on older adults—offers guidance on deintensification. Websites such as deprescribing.org supply algorithm-based protocols for common drug classes. Additionally, the CDC National Diabetes Statistics Report provides population-level context that can inform risk stratification. Primary care clinics without access to a geriatrician can leverage telehealth consultations with a clinical pharmacist specializing in older adult polypharmacy.

Guideline-Based Approach

Management should align with current evidence, but guidelines must be applied flexibly in older adults. Most diabetes trials that drove aggressive glycemic targets excluded patients aged 75+ with multimorbidity or frailty. Therefore, the 2024 ADA Standards of Care recommend individualizing A1c goals: for healthy older adults with few comorbidities, target <7.5%; for those with intermediate health, <8.0%; and for those with complex/poor health, <8.5%. Similarly, blood pressure targets may be relaxed in older adults at high risk of falls. Every guideline recommendation for a drug—whether metformin, statin, or SGLT2 inhibitor—should be weighed against the patient’s remaining life expectancy, functional status, and personal preferences. When prescribing a new drug, always ask whether there is a simpler alternative or whether an existing drug could be adjusted instead of adding.

Future Directions and Research Gaps

Current deprescribing evidence is largely observational; large randomized trials are needed to confirm the safety and efficacy of deprescribing protocols in older diabetic populations. Pragmatic trials comparing structured deprescribing with usual care—and measuring outcomes such as falls, cognitive decline, hospitalization rates, and quality of life—would greatly strengthen the evidence base. Research is also needed on patient decision aids that support shared deprescribing, on integrating polypharmacy metrics into electronic health records, and on the role of artificial intelligence in flagging problematic regimens in real time. The growing availability of composite endpoints in geriatric trials may finally provide the data required to move polypharmacy management from expert opinion to evidence-based practice.

Conclusion

Polypharmacy in older adults with diabetes is not an inevitable consequence of aging but a modifiable clinical challenge that can be systematically addressed in primary care. Through regular medication reconciliation, deliberate deprescribing, regimen simplification, shared decision-making with patients, and interdisciplinary teamwork, clinicians can reduce adverse drug events, improve adherence, and enhance patient well-being. By adopting a proactive, patient-centered framework—and applying tools like the Beers Criteria, STOPP/START, and deprescribing.org protocols—primary care providers can deliver safer, more effective care for this vulnerable population. Ultimately, the goal is not merely to reduce the number of pills, but to align medication therapy with what truly matters most to each older adult living with diabetes.

Further reading: For additional detail, refer to the ADA Standards of Care and the AGS Beers Criteria.